5-Minute Pharma Daily(feeds.transistor.fm)
Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competitionZealand sells milestone, royalty rights to rare blood cancer asset for up to $100MBankrupt Sangamo offloads assets to Lilly, PTC in $161M saleThe Italian inflection point: Clinical strength, culture and capitalBehind the bell: Gearing up to go publicJuly's biopharma layoffs affect 466 employees, a 94% year-over-year dropDeaths reported after treatment with Neurocrine’s approved Prader-Willi drug
BioPharma Dive - Latest News(biopharmadive.com)
New Taiho, Cullian data heats up lung cancer drug battlePTC takes a chance on Sangamo’s Fabry disease gene therapyLilly files six lawsuits in bid to shut down ‘black market’ for retatrutidePsychedelics developer Definium scores more positive data for LSD pillSilence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccinesBoulevard starts up with $65M to pursue targeted autoimmune drugsEx-Legend CEO takes helm at biotech startup scouring the globe for drugs
Bristol Myers Squibb's $2.3B Texas Investment Boosts Jobs | Pharma and Biotech DailyNovo Nordisk & AWS Partner for AI Drug Discovery Breakthrough | Pharma and Biotech DailyReplimune's FDA Win: Tudriqev Approved After 2 Rejections | Pharma and Biotech DailyModerna mRNA Flu Vaccine Approved by FDA | Pharma and Biotech DailyEli Lilly's $23B Q2 Revenue Breaks Records | Pharma and Biotech DailyOtsuka's Voyxact Shines in Phase 3 Trial | Pharma and Biotech DailySupernus & Indivior $2.2B Merger Creates CNS Giant | Pharma and Biotech Daily
Kupando doses first patient in phase 1 trialFirst-in-class house dust mite allergy treatment now available in ScotlandNHS backs new treatment option for cystinosisFridge‑free vaccine shows global potentialLexeo wins FDA RMAT status for LX2020EHP Awards 2027 open for entriesNICE backs new blood cancer regimens
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug classTwo years after rules overhaul, have methadone clinics really changed?Opinion: MAHA and insurance companies both want to treat human bodies like carsOpinion: U.S., U.K. health care systems share a fatal flawHow will legal challenges fare against CMS rule on gender-affirming care?STAT+: Commure terminates payments under its customer referral programs tied to AI productsSTAT+: Eli Lilly targets booming black market for retatrutide